



Research Article

Volume 23 Issue 5 - April 2023

DOI: 10.19080/CTOIJ.2023.23.556122

Cancer Ther Oncol Int J

Copyright © All rights are reserved by Murat Beyzadeoglu

An Original Article Revisiting the Utility of Multimodality Imaging For Refined Target Volume Determination Of Recurrent Kidney Carcinoma



Murat Beyzadeoglu*, Ferrat Dincoglan, Selcuk Demiral and Omer Sager

Department of Radiation Oncology; University of Health Sciences, Gulhane Medical Faculty, Ankara, Turkey

Submission: April 20, 2023; Published: April 28, 2023

*Corresponding author: Dr. Murat Beyzadeoglu, University of Health Sciences, Gulhane Medical Faculty,

Department of Radiation Oncology, Gn.Tevfik Saglam Cad. 06018, Etlik, Kecioren, Ankara, Turkey, E-mail: drmuratbeyzadeoglu@gmail.com

Abstract

Objective: Cancers of the kidney include a variety of histological subtypes with different disease processes and clinical behaviour. Renal cell carcinoma (RCC) arises from the renal cortex, and accounts for the majority of kidney cancers. Radiation therapy (RT) may serve as a viable modality for management of kidney cancer. Currently, Computed Tomography (CT) simulation serves as a widely accepted method for acquisition of RT planning images. Nevertheless, incorporation of other imaging modalities such as Magnetic Resonance Imaging (MRI) may possibly improve the precision of targeting. In this original research article, we would like to investigate the utility of multimodality imaging for refined target volume determination of recurrent kidney carcinoma.

Materials and Methods: Included patients were those referred to Department of Radiation Oncology at Gulhane Medical Faculty, University of Health Sciences for recurrent kidney cancer management. Focused subject of our investigation was about target definition by CT only imaging or by integration of fused CT-MRI.

Results: We have performed a comparative assessment for target and critical organ definition by use of either CT only imaging or by fused CT-MRI. Lesion size, location and association with critical surrounding structures were all considered for optimal RT planning. As for the result of this study, comparative analysis by using the ground truth target volume as the reference demonstrated that use of fused CT-MRI based target definition was identical with ground truth target volume definition for patients irradiated for recurrent kidney cancer.

Conclusion: This study supports the utility of multimodality imaging for accurate RT of recurrent kidney cancers. Admittedly, further studies may be required address this important aspect of radiotherapeutic management.

Abbreviations: Recurrent kidney cancer; Radiation therapy (RT); Magnetic Resonance Imaging (MRI)

Introduction

Cancers of the kidney include a variety of histological subtypes with different disease processes and clinical behaviour. Renal cell carcinoma (RCC) arises from the renal cortex, and accounts for the majority of kidney cancers. Subtypes of RCC include clear cell, papillary, chromophobe, and oncocytoma variants. Local failure is a known pattern of recurrence for kidney cancers, and multidisciplinary management plays a central role for optimal treatment. Radiation therapy (RT) may serve as a viable modality for management of kidney cancer [1-4].

In the millennium era, advances in therapy of kidney cancer lead to potentially improved treatment results, and issues regarding

quality of life and critical organ sparing may be considered as important aspects of radiotherapeutic management. Molecular imaging techniques, automatic segmentation methods, Intensity Modulated RT (IMRT), stereotactic RT, Image Guided RT (IGRT), and adaptive RT (ART) strategies critically refined the implementation of RT [5-45]. However, major advances have come up with the requirement for improved target definition which should be regarded as a very critical part of contemporary radiotherapeutic management. Currently, Computed Tomography (CT) simulation serves as a widely accepted method for acquisition of RT planning images. Nevertheless, incorporation of other imaging modalities such as Magnetic Resonance Imaging (MRI) may possibly improve

the precision of targeting and this critical issue has been mentioned by many different studies in the existing body of literature [46-84]. By virtue of this original research article, we would like to emphasize the utility of multimodality imaging for refined target volume determination of recurrent kidney carcinoma.

Materials and Methods

Included patients were those referred to Department of Radiation Oncology at Gulhane Medical Faculty, University of Health Sciences for recurrent kidney cancer management. Focused subject of our investigation was about target definition by CT only imaging or by integration of fused CT-MRI. We have conducted a comparative analysis to assess target definition with CT simulation images only or with incorporation of MRI. As a critical endpoint, principal outcome measure has been to find out the utility of multimodality imaging for target definition of recurrent kidney cancers, nevertheless, delineation of normal tissues, interobserver and intraobserver variations have also been evaluated. Comparative analysis has been done, and the ground truth target volume was considered as the reference. Ground truth target volume delineation was a critical procedure which has been run by board certified radiation oncologists with detailed evaluation of all imaging and other data accompanied by meticulous colleague peer review and collaboration. Treatment decisions have been taken after critical and individualized patient assessment with multidisciplinary input from experts on surgical oncology, radiation oncology, and medical oncology. Patient, disease, and treatment related parameters were all assessed. Previously delivered therapies, patient age, symptomatology, lesion size and localization, performance status, contemplated outcomes of suggested therapies, patient preferences and logistical issues have all been considered in the decision making process.

Irradiation has been performed by use of a Linear Accelerator (LINAC) furnished with the sophisticated IGRT technology. After immobilization of the patients, planning CT images were acquired at the CT simulator for radiation treatment planning. Later, obtained RT planning images have been transferred to the delineation workstation via the network. Target volumes and normal tissues have been defined on these images and structure sets have been generated for the patients. Either CT simulation images only or fused CT-MR images were utilized for the purpose of comparative evaluation with detailed analysis.

Results

Our purpose was to address the role of multimodality imaging with integration of MRI for radiotherapeutic management of recurrent kidney cancer in this original research article. Irradiation of patients has been executed in Radiation Oncology Department of Gulhane Medical Faculty at University of Health

Sciences, Ankara. Prior to initiation of RT, all patients were evaluated by multidisciplinary input from relevant disciplines of surgical oncology, radiation oncology, and medical oncology. To summarize, we have performed a comparative assessment for target and critical organ definition by use of either CT only imaging or by fused CT-MRI. Lesion size, location and association with critical surrounding structures were all considered for optimal RT planning. Also, radiation physicists who had expertise on this subject were involved in RT planning process with consideration of reports by American Association of Physicists in Medicine (AAPM) and International Commission on Radiation Units and Measurements (ICRU). Precise RT planning process included critical consideration of electron density, tissue heterogeneity, CT number and HU values in CT images. An important objective of radiation treatment planning was to maintain optimal target coverage with minimal exposure of surrounding normal tissues. As for the result of this study, comparative analysis by using the ground truth target volume as the reference demonstrated that use of fused CT-MRI based target definition was identical with ground truth target volume definition for patients irradiated for recurrent kidney cancer.

Discussion

Kidney cancers may include a variety of histological subtypes which may exhibit different disease processes and clinical behaviour. RCC originates from the renal cortex, and accounts for majority of kidney cancers. RCC subtypes include clear cell, papillary, chromophobe, and oncocytoma variants. Local failure may be considered as an important pattern of recurrence for kidney cancers, and collaborative management plays a critical role for optimal treatment. RT may be regarded as a viable modality for management of kidney cancers [1-4].

Recently, advances in therapy of kidney cancer lead to potentially improved treatment results, and issues regarding quality of life and critical organ sparing may be considered as important aspects of radiotherapeutic management. Intensity Modulated RT (IMRT), stereotactic RT, Image Guided RT (IGRT), and adaptive RT (ART) strategies along with molecular imaging techniques and automatic segmentation methods have refined the use of RT [5-45]. Nevertheless, these major advances warrant the need for improved target definition as a critical component of sophisticated RT strategies. In the meantime, CT simulation remains to be the widely accepted technique for acquisition of RT planning images. However, incorporation of other imaging modalities such as MRI may potentially improve the accuracy of targeting, and this aspect of radiotherapeutic management was addressed in several studies [46-84]. By conducting this study, we aimed to emphasize the role of multimodality imaging for refined target volume determination of recurrent kidney cancers.

Conclusion

In conclusion, this study supports the role of multimodality imaging for accurate RT of recurrent kidney cancers. Admittedly, further studies may be required address this important aspect of radiotherapeutic management.

Conflict of Interest

There are no conflicts of interest and no acknowledgements.

References

1. Christensen M, Hannan R (2022) The Emerging Role of Radiation Therapy in Renal Cell Carcinoma. *Cancers (Basel)* 14(19): 4693.
2. Mourad WF, Dutcher J, Ennis RD (2014) State-of-the-art management of renal cell carcinoma. *Am J Clin Oncol* 37(5): 498-505.
3. Siva S, Kothari G, Muacevic A, Louie AV, Slotman BJ, et al. (2017) Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. *Nat Rev Urol* 14(9): 549-563.
4. Spyropoulou D, Tsiganos P, Dimitrakopoulos FI, Tolia M, Koutras A, et al. (2021) Radiotherapy and Renal Cell Carcinoma: A Continuing Saga. *In Vivo* 35(3): 1365-1377.
5. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2022) Adaptive radiation therapy (ART) for patients with limited-stage small cell lung cancer (LS-SCLC): A dosimetric evaluation. *Indian J Cancer*.
6. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2022) Potential Utility of Radiopharmaceuticals in the Battle Against SARS-CoV-2 and COVID-19 Pandemic. *Curr Radiopharm* 15(2): 93-95.
7. Oktay EA, Zerener T, Dirican B, Yildiz S, Sager O, et al. (2022) Dosimetric evaluation of the effect of dental restorative materials in head and neck radiotherapy. *Indian J Cancer* 59(3): 402-407.
8. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2022) Concise review of radiosurgery for contemporary management of pilocytic astrocytomas in children and adults. *World J Exp Med* 12(3): 36-43.
9. Gamsiz H, Sager O, Uysal B, Dincoglan F, Demiral S, et al. (2022) Active breathing control guided stereotactic body ablative radiotherapy for management of liver metastases from colorectal cancer. *Acta Gastroenterol Belg* 85(3): 1-7.
10. Sager O, Dincoglan F, Demiral S, Gamsiz H, Uysal B, et al. (2022) Optimal timing of thoracic irradiation for limited stage small cell lung cancer: Current evidence and future prospects. *World J Clin Oncol* 13(2): 116-124.
11. Demiral S, Sager O, Dincoglan F, Uysal B, Gamsiz H, et al. (2021) Evaluation of breathing-adapted radiation therapy for right-sided early stage breast cancer patients. *Indian J Cancer* 58(2): 195-200.
12. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2021) Omission of Radiation Therapy (RT) for Metaplastic Breast Cancer (MBC): A Review Article. *International Journal of Research Studies in Medical and Health Sciences* 6(1): 10-15.
13. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2021) Concise review of stereotactic irradiation for pediatric gliial neoplasms: Current concepts and future directions. *World J Methodol* 11(3): 61-74.
14. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2020) Adaptive radiation therapy of breast cancer by repeated imaging during irradiation. *World J Radiol* 12(5): 68-75.
15. Sager O, Beyzadeoglu M, Dincoglan F, Demiral S, Gamsiz H, et al. (2020) Multimodality management of cavernous sinus meningiomas with less extensive surgery followed by subsequent irradiation: Implications for an improved toxicity profile. *J Surg Surgical Res* 6: 056-061.
16. Beyzadeoglu M, Sager O, Dincoglan F, Demiral S, Uysal B, et al. (2020) Single Fraction Stereotactic Radiosurgery (SRS) versus Fractionated Stereotactic Radiotherapy (FSRT) for Vestibular Schwannoma (VS). *J Surg Surgical Res* 6(1): 062-066.
17. Dincoglan F, Beyzadeoglu M, Sager O, Demiral S, Uysal B, et al. (2020) A Concise Review of Irradiation for Temporal Bone Chemodectomas (TBC). *Arch Otolaryngol Rhinol* 6(2): 016-020.
18. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2019) Utility of Molecular Imaging with 2-Deoxy-2-[Fluorine-18] Fluoro-DGlucose Positron Emission Tomography (18F-FDG PET) for Small Cell Lung Cancer (SCLC): A Radiation Oncology Perspective. *Curr Radiopharm* 12(1): 4-10.
19. Dincoglan F, Sager O, Demiral S, Gamsiz H, Uysal B, et al. (2019) Fractionated stereotactic radiosurgery for locally recurrent brain metastases after failed stereotactic radiosurgery. *Indian J Cancer* 56(2): 151-156.
20. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2019) Breathing adapted radiation therapy for leukemia relapse in the breast: A case report. *World J Clin Oncol* 10(11): 369-374.
21. Dincoglan F, Sager O, Uysal B, Demiral S, Gamsiz H, et al. (2019) Evaluation of hypofractionated stereotactic radiotherapy (HFSRT) to the resection cavity after surgical resection of brain metastases: A single center experience. *Indian J Cancer* 56(3): 202-206.
22. Sager O, Dincoglan F, Uysal B, Demiral S, Gamsiz H, et al. (2018) Evaluation of adaptive radiotherapy (ART) by use of replanning the tumor bed boost with repeated computed tomography (CT) simulation after whole breast irradiation (WBI) for breast cancer patients having clinically evident seroma. *Jpn J Radiol* 36(6): 401-406.
23. Demiral S, Dincoglan F, Sager O, Uysal B, Gamsiz H, et al. (2018) Contemporary Management of Meningiomas with Radiosurgery. *Int J Radiol Imaging Technol* 80: 187-190.
24. Sager O, Dincoglan F, Uysal B, Demiral S, Gamsiz H, et al. (2017) Splenic Irradiation: A Concise Review of the Literature. *J App Hem Bl Tran* 1: 101.
25. Dincoglan F, Sager O, Demiral S, Uysal B, Gamsiz H, et al. (2017) Radiosurgery for recurrent glioblastoma: A review article. *Neurol Disord Therap* 1: 1-5.
26. Demiral S, Dincoglan F, Sager O, Gamsiz H, Uysal B, et al. (2016) Hypofractionated stereotactic radiotherapy (HFSRT) for who grade I anterior clinoid meningiomas (ACM). *Jpn J Radiol* 34(11): 730-737.
27. Dincoglan F, Beyzadeoglu M, Sager O, Demiral S, Gamsiz H, et al. (2015) Management of patients with recurrent glioblastoma using hypofractionated stereotactic radiotherapy. *Tumori* 101(2): 179-184.
28. Gamsiz H, Beyzadeoglu M, Sager O, Demiral S, Dincoglan F, et al. (2015) Evaluation of stereotactic body radiation therapy in the management of adrenal metastases from non-small cell lung cancer. *Tumori* 101(1): 98-103.
29. Sager O, Beyzadeoglu M, Dincoglan F, Demiral S, Uysal B, et al. (2015) Adaptive splenic radiotherapy for symptomatic splenomegaly management in myeloproliferative disorders. *Tumori* 101(1): 84-90.
30. Sager O, Dincoglan F, Beyzadeoglu M (2015) Stereotactic radiosurgery of glomus jugulare tumors: Current concepts, recent advances and future perspectives. *CNS Oncol* 4(2): 105-114.
31. Sager O, Beyzadeoglu M, Dincoglan F, Uysal B, Gamsiz H, et al. (2014) Evaluation of linear accelerator (LINAC)-based stereotactic radiosurgery (SRS) for cerebral cavernous malformations: A 15-year single-center experience. *Ann Saudi Med* 34(1): 54-58.

32. Demiral S, Beyzadeoglu M, Sager O, Dincoglan F, Gamsiz H, et al. (2014) Evaluation of Linear Accelerator (Linac)-Based Stereotactic Radiosurgery (Srs) for the Treatment of Craniopharyngiomas. UHOD - Uluslararası Hematoloji-Onkoloji Dergisi 24(2): 123-129.
33. Sager O, Beyzadeoglu M, Dincoglan F, Gamsiz H, Demiral S, et al. (2014) Evaluation of linear accelerator-based stereotactic radiosurgery in the management of glomus jugulare tumors. Tumori 100(2): 184-188.
34. Ozsavas EE, Telatar Z, Dirican B, Sager O, Beyzadeoglu M (2014) Automatic segmentation of anatomical structures from CT scans of thorax for RTP. Comput Math Methods Med 2014: 472890.
35. Demiral S, Beyzadeoglu M, Sager O, Dincoglan F, Gamsiz H, et al. (2014) Evaluation of linear accelerator (linac)-based stereotactic radiosurgery (srs) for the treatment of craniopharyngiomas. UHOD - Uluslararası Hematoloji-Onkoloji Dergisi 24: 123-129.
36. Gamsiz H, Beyzadeoglu M, Sager O, Dincoglan F, Demiral S, et al. (2014) Management of pulmonary oligometastases by stereotactic body radiotherapy. Tumori 100(2): 179-183.
37. Dincoglan F, Sager O, Gamsiz H, Uysal B, Demiral S, et al. (2014) Management of patients with ≥ 4 brain metastases using stereotactic radiosurgery boost after whole brain irradiation. Tumori 100(3): 302-306.
38. Sager O, Beyzadeoglu M, Dincoglan F, Demiral S, Uysal B, et al. (2013) Management of vestibular schwannomas with linear accelerator-based stereotactic radiosurgery: a single center experience. Tumori 99(5): 617-622.
39. Dincoglan F, Beyzadeoglu M, Sager O, Uysal B, Demiral S, et al. (2013) Evaluation of linear accelerator-based stereotactic radiosurgery in the management of meningiomas: A single center experience. J BUON 18(3): 717-722.
40. Dincoglan F, Beyzadeoglu M, Sager O, Oysul K, Kahya YE, et al. (2013) Dosimetric evaluation of critical organs at risk in mastectomized left-sided breast cancer radiotherapy using breath-hold technique. Tumori 99(1): 76-82.
41. Demiral S, Beyzadeoglu M, Uysal B, Oysul K, Kahya YE, et al. (2013) Evaluation of stereotactic body radiotherapy (SBRT) boost in the management of endometrial cancer. Neoplasma 60(3): 322-327.
42. Sager O, Beyzadeoglu M, Dincoglan F, Oysul K, Kahya YE, et al. (2012) Evaluation of active breathing control-moderate deep inspiration breath-hold in definitive non-small cell lung cancer radiotherapy. Neoplasma 59(3): 333-340.
43. Sager O, Dincoglan F, Gamsiz H, Demiral S, Uysal B, et al. (2012) Evaluation of the impact of integrated [18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging on staging and radiotherapy treatment volume definition of nonsmall cell lung cancer. Gulhane Med J 54: 220-227.
44. Sager O, Beyzadeoglu M, Dincoglan F, Oysul K, Kahya YE, et al. (2012) The Role of Active Breathing Control-Moderate Deep Inspiration Breath-Hold (ABC-mDIBH) Usage in non-Mastectomized Left-sided Breast Cancer Radiotherapy: A Dosimetric Evaluation UHOD - Uluslararası Hematoloji-Onkoloji Dergisi 22(3): 147-155.
45. Dincoglan F, Sager O, Gamsiz H, Uysal B, Demiral S, et al. (2012) Stereotactic radiosurgery for intracranial tumors: A single center experience. Gulhane Med J 54: 190-198.
46. Dincoglan F, Beyzadeoglu M, Sager O, Oysul K, Sirin S et al. (2012) Image-guided positioning in intracranial non-invasive stereotactic radiosurgery for the treatment of brain metastasis. Tumori 98(5): 630-635.
47. Sirin S, Oysul K, Surenkok S, Sager O, Dincoglan F, et al. (2011) Linear accelerator-based stereotactic radiosurgery in recurrent glioblastoma: A single center experience. Vojnosanit Pregl 68(11): 961-966.
48. Beyzadeoglu M, Demiral S, Dincoglan F, Sager O (2022) Assessment of Target Definition for Extramedullary Soft Tissue Plasmacytoma: Use of Multimodality Imaging for Improved Targeting Accuracy. Canc Therapy & Oncol Int J 22(4): 556095.
49. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2022) Target Volume Determination for Recurrent Uterine Carcinosarcoma: An Original Research Article Revisiting the Utility of Multimodality Imaging. Canc Therapy & Oncol Int J 22(3): 556090.
50. Demiral S, Sager O, Dincoglan F, Beyzadeoglu M (2022) Reappraisal of Computed Tomography (CT) And Magnetic Resonance Imaging (MRI) Based Target Definition for Radiotherapeutic Management of Recurrent Anal Squamous Cell Carcinoma (ASCC): An Original Article. Canc Therapy & Oncol Int J 22(2): 556085.
51. Demiral S, Dincoglan F, Sager O, Beyzadeoglu M (2022) An Original Article for Assessment of Multimodality Imaging Based Precise Radiation Therapy (Rt) in the Management of Recurrent Pancreatic Cancers. Canc Therapy & Oncol Int J 22(1): 556078.
52. Sager O, Demiral S, Dincoglan F, Beyzadeoglu M (2022) Assessment of Target Volume Definition for Precise Radiotherapeutic Management of Locally Recurrent Biliary Tract Cancers: An Original Research Article. Biomed J Sci & Tech Res 46(1): 37054-37059.
53. Sager O, Demiral S, Dincoglan F, Beyzadeoglu M. (2022) Radiation Therapy (RT) Target Volume Determination for Locally Advanced Pyriform Sinus Carcinoma: An Original Research Article Revisiting the Role of Multimodality Imaging. Biomed J Sci & Tech Res 45(1): 36155-36160.
54. Demiral S, Sager O, Dincoglan F, Beyzadeoglu M (2022) Improved Target Volume Definition for Radiotherapeutic Management of Parotid Gland Cancers by use of Multimodality Imaging: An Original Article. Canc Therapy & Oncol Int J 21(3): 556062.
55. Beyzadeoglu M, Sager O, Demiral S, Dincoglan F (2022) Reappraisal of multimodality imaging for improved Radiation Therapy (RT) target volume determination of recurrent Oral Squamous Cell Carcinoma (OSCC): An original article. J Surg Surgical Res 8(1): 004-008.
56. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2022) Multimodality imaging based treatment volume definition for recurrent Rhabdomyosarcomas of the head and neck region: An original article. J Surg Surgical Res 8(2): 013-018.
57. Dincoglan F, Demiral S, Sager O, Beyzadeoglu M (2022) Appraisal of Target Definition for Management of Paraspinal Ewing Tumors with Modern Radiation Therapy (RT): An Original Article. Biomed J Sci & Tech Res 44(4): 35691-35696.
58. Beyzadeoglu M, Sager O, Demiral S, Dincoglan F (2022) Assessment of Target Volume Definition for Contemporary Radiotherapeutic Management of Retroperitoneal Sarcoma: An Original Article. Biomed J Sci & Tech Res 44(5): 35883-35887.
59. Demiral S, Dincoglan F, Sager O, Beyzadeoglu M (2021) Assessment of Multimodality Imaging for Target Definition of Intracranial Chondrosarcomas. Canc Therapy Oncol Int J 18(2): 001-005.
60. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2021) Impact of Multimodality Imaging to Improve Radiation Therapy (RT) Target Volume Definition for Malignant Peripheral Nerve Sheath Tumor (MPNST). Biomed J Sci Tech Res 34(3): 26734-26738.
61. Sager O, Demiral S, Dincoglan F, Beyzadeoglu M (2021) Multimodality Imaging Based Treatment Volume Definition for Reirradiation of Recurrent Small Cell Lung Cancer (SCLC). Arch Can Res 9(1): 1-5.

62. Demiral S, Sager O, Dincoglan F, Beyzadeoglu M (2021) Radiation Therapy (RT) Target Volume Definition for Peripheral Primitive Neuroectodermal Tumor (PPNET) by Use of Multimodality Imaging: An Original Article. *Biomed J Sci & Tech Res* 34(4): 26970-26974.
63. Dincoglan F, Demiral S, Sager O, Beyzadeoglu M (2021) Evaluation of Target Definition for Management of Myxoid Liposarcoma (MLS) with Neoadjuvant Radiation Therapy (RT). *Biomed J Sci Tech Res* 33(5): 26171-26174.
64. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2021) Radiation Therapy (RT) target determination for irradiation of bone metastases with soft tissue component: Impact of multimodality imaging. *J Surg Surgical Res* 7(1): 042-046.
65. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2021) Evaluation of Changes in Tumor Volume Following Upfront Chemotherapy for Locally Advanced Non Small Cell Lung Cancer (NSCLC). *Glob J Cancer Ther* 7(1): 031-034.
66. Sager O, Demiral S, Dincoglan F, Beyzadeoglu M (2021) Assessment of posterior fossa target definition by multimodality imaging for patients with medulloblastoma. *J Surg Surgical Res* 7(1): 037-041.
67. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2021) Assessment of the role of multimodality imaging for treatment volume definition of intracranial ependymal tumors: An original article. *Glob J Cancer Ther* 7(1): 043-045.
68. Beyzadeoglu M, Dincoglan F, Demiral S, Sager O (2020) Target Volume Determination for Precise Radiation Therapy (RT) of Central Neurocytoma: An Original Article. *International Journal of Research Studies in Medical and Health Sciences* 5(3): 29-34.
69. Dincoglan F, Demiral S, Sager O, Beyzadeoglu M (2020) Utility of Multimodality Imaging Based Target Volume Definition for Radiosurgery of Trigeminal Neuralgia: An Original Article. *Biomed J Sci & Tech Res* 26: 19728-19732.
70. Demiral S, Beyzadeoglu M, Dincoglan F, Sager O (2020) Assessment of Target Volume Definition for Radiosurgery of Atypical Meningiomas with Multimodality Imaging. *Journal of Hematology and Oncology Research* 3(4): 14-21.
71. Dincoglan F, Beyzadeoglu M, Demiral S, Sager O (2020) Assessment of Treatment Volume Definition for Irradiation of Spinal Ependymomas: an Original Article. *ARC Journal of Cancer Science* 6(1): 1-6.
72. Sager O, Demiral S, Dincoglan F, Beyzadeoglu M (2020) Target Volume Definition for Stereotactic Radiosurgery (SRS) Of Cerebral Cavernous Malformations (CCMs). *Canc Therapy & Oncol Int J* 15(4): 555917.
73. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2020) Treatment Volume Determination for Irradiation of Recurrent Nasopharyngeal Carcinoma with Multimodality Imaging: An Original Article. *ARC Journal of Cancer Science* 6(2): 18-23.
74. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2020) Assessment of Target Volume Definition for Irradiation of Hemangiopericytomas: An Original Article. *Canc Therapy & Oncol Int J* 17(2): 555959.
75. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2020) Evaluation of Treatment Volume Determination for Irradiation of chordoma: an Original Article. *International Journal of Research Studies in Medical and Health Sciences* 5(10): 3-8.
76. Demiral S, Dincoglan F, Sager O, Beyzadeoglu M (2020) Multimodality Imaging Based Target Definition of Cervical Lymph Nodes in Precise Limited Field Radiation Therapy (LfRT) for Nodular Lymphocyte Predominant Hodgkin Lymphoma (NlphL). *ARC Journal of Cancer Science* 6(2): 06-11.
77. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2020) Radiosurgery Treatment Volume Determination for Brain Lymphomas with and without Incorporation of Multimodality Imaging. *Journal of Medical Pharmaceutical and Allied Sciences* 9(1): 2398-2404.
78. Beyzadeoglu M, Dincoglan F, Sager O, Demiral S (2020) Determination of Radiosurgery Treatment Volume for Intracranial Germ Cell Tumors (GCTs). *Asian Journal of Pharmacy, Nursing and Medical Sciences* 8(3): 18-23.
79. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2020) Target Definition of orbital Embryonal Rhabdomyosarcoma (Rms) by Multimodality Imaging: An Original Article. *ARC Journal of Cancer Science* 6(2): 12-17.
80. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2020) Evaluation of Target Volume Determination for Irradiation of Pilocytic Astrocytomas: An Original Article. *ARC Journal of Cancer Science* 6(1): 1-5.
81. Demiral S, Beyzadeoglu M, Dincoglan F, Sager O (2020) Evaluation of Radiosurgery Target Volume Definition for Tectal Gliomas with Incorporation of Magnetic Resonance Imaging (MRI): An Original Article. *Biomedical Journal of Scientific & Technical Research (BJSTR)* 27: 20543-20547.
82. Beyzadeoglu M, Sager O, Dincoglan F, Demiral S (2019) Evaluation of Target Definition for Stereotactic Reirradiation of Recurrent Glioblastoma. *Arch Can Res* 7(1): 3.
83. Sager O, Dincoglan F, Demiral S, Gamsiz H, Uysal B, et al. (2019) Evaluation of the Impact of Magnetic Resonance Imaging (MRI) on Gross Tumor Volume (GTV) Definition for Radiation Treatment Planning (RTP) of Inoperable High Grade Gliomas (HGGs). *Concepts in Magnetic Resonance Part A* 2019: 4282754.
84. Sager O, Dincoglan F, Demiral S, Gamsiz H, Uysal B, et al. (2019) Utility of Magnetic Resonance Imaging (Imaging) in Target Volume Definition for Radiosurgery of Acoustic Neuromas. *Int J Cancer Clin Res* 6: 119.
85. Demiral S, Sager O, Dincoglan F, Beyzadeoglu M (2019) Assessment of Computed Tomography (CT) And Magnetic Resonance Imaging (MRI) Based Radiosurgery Treatment Planning for Pituitary Adenomas. *Canc Therapy & Oncol Int J* 13(2): 555857.
86. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2019) Multimodality Imaging for Radiosurgical Management of Arteriovenous Malformations. *Asian Journal of Pharmacy, Nursing and Medical Sciences* 7(1): 7-12.
87. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2019) Evaluation of Radiosurgery Target Volume Determination for Meningiomas Based on Computed Tomography (CT) And Magnetic Resonance Imaging (MRI). *Cancer Sci Res Open Access* 5(2): 1-4.
88. Demiral S, Sager O, Dincoglan F, Beyzadeoglu M (2019) Assessment of target definition based on Multimodality imaging for radiosurgical Management of glomus jugulare tumors (GJTs). *Canc Therapy & Oncol Int J* 15(2): 555909.
89. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2019) Incorporation of Multimodality Imaging in Radiosurgery Planning for Craniopharyngiomas: An Original Article. *SAJ Cancer Sci* 6: 103.
90. Demiral S, Sager O, Dincoglan F, Uysal B, Gamsiz H, et al. (2018) Evaluation of Target Volume Determination for Single Session Stereotactic Radiosurgery (SRS) of Brain Metastases. *Canc Therapy & Oncol Int J* 12(5): 555848.



This work is licensed under Creative Commons Attribution 4.0 License
DOI: [10.19080/CTOIJ.2023.23.556122](https://doi.org/10.19080/CTOIJ.2023.23.556122)

**Your next submission with Juniper Publishers
will reach you the below assets**

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats
(**Pdf, E-pub, Full Text, Audio**)
- Unceasing customer service

Track the below URL for one-step submission

<https://juniperpublishers.com/online-submission.php>